These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11049104)

  • 1. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.
    Poeze M; Froon AH; Ramsay G; Buurman WA; Greve JW
    Shock; 2000 Oct; 14(4):421-8. PubMed ID: 11049104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial.
    Froon AM; Greve JW; Buurman WA; van der Linden CJ; Langemeijer HJ; Ulrich C; Bourgeois M
    Shock; 1996 May; 5(5):313-9. PubMed ID: 9156785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock.
    Angstwurm MW; Engelmann L; Zimmermann T; Lehmann C; Spes CH; Abel P; Strauss R; Meier-Hellmann A; Insel R; Radke J; Schüttler J; Gärtner R
    Crit Care Med; 2007 Jan; 35(1):118-26. PubMed ID: 17095947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of TCV-309--a potent PAF antagonist.
    Terashita Z; Takatani M; Nishikawa K
    J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
    Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP
    Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the platelet-activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock.
    Yamanaka S; Iwao H; Yukimura T; Kim S; Miura K
    Br J Pharmacol; 1993 Dec; 110(4):1501-7. PubMed ID: 8306093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
    Okano S; Tagawa M; Urakawa N
    J Vet Med Sci; 1995 Aug; 57(4):751-3. PubMed ID: 8519912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac functional and structural alterations induced by endotoxin in rats: importance of platelet-activating factor.
    Iwase M; Yokota M; Kitaichi K; Wang L; Takagi K; Nagasaka T; Izawa H; Hasegawa T
    Crit Care Med; 2001 Mar; 29(3):609-17. PubMed ID: 11373429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan.
    Ogata M; Matsumoto T; Koga K; Takenaka I; Kamochi M; Sata T; Yoshida S; Shigematsu A
    Infect Immun; 1993 Feb; 61(2):699-704. PubMed ID: 8423096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
    Kawamura M; Kitayoshi T; Terashita Z; Fujiwara S; Takatani M; Nishikawa K
    J Lipid Mediat Cell Signal; 1994 May; 9(3):255-65. PubMed ID: 7921785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.
    Johnson CD; Kingsnorth AN; Imrie CW; McMahon MJ; Neoptolemos JP; McKay C; Toh SK; Skaife P; Leeder PC; Wilson P; Larvin M; Curtis LD
    Gut; 2001 Jan; 48(1):62-9. PubMed ID: 11115824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluconazole improves survival in septic shock: a randomized double-blind prospective study.
    Jacobs S; Price Evans DA; Tariq M; Al Omar NF
    Crit Care Med; 2003 Jul; 31(7):1938-46. PubMed ID: 12847386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock.
    Okano S; Tagawa M; Urakawa N
    J Vet Med Sci; 1995 Apr; 57(2):385-7. PubMed ID: 7492672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
    Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
    Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.
    Warren BL; Eid A; Singer P; Pillay SS; Carl P; Novak I; Chalupa P; Atherstone A; Pénzes I; Kübler A; Knaub S; Keinecke HO; Heinrichs H; Schindel F; Juers M; Bone RC; Opal SM;
    JAMA; 2001 Oct; 286(15):1869-78. PubMed ID: 11597289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-activating factor antagonist (TCV-309) attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats.
    Yamaguchi Y; Matsumura F; Liang J; Okabe K; Matsuda T; Ohshiro H; Ishihara K; Akizuki E; Yamada S; Ogawa M
    Pancreas; 1999 May; 18(4):355-63. PubMed ID: 10231840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.